KOL Knockout: Headache Edition: Novel Preventative and Acute

Overview
Several novel therapies, including pharmacological agents and devices, for the treatment of migraine have recently entered the market and additional therapies are on the horizon. These therapies offer options for patients who have migraine that is refractory to treatment or who are unable to use existing migraine treatments due to tolerability issues or contraindications.Supported by an educational grant from Biohaven Pharmaceuticals.
Learning Objectives
This initiative is designed to address and resolve the educational needs through the following educational objectives:
- Diagnose migraine comorbidities and coexisting headache disorders, appraise the available tools and execute management strategies for these conditions.
- Recognize patients who are in need of preventive therapy for migraines and distinguish among existing and novel preventive therapies for migraine, specifically CGRP-antibodies and their mechanism of their action.
- Rate acute medication options for treatment of migraine, including the newer acute therapies, ubrogepant, rimegepant and lasmiditan, and explain their mechanism of action and the indications for their use.
- Compare neuro-modulatory devices that are approved for use in treatment of migraine and the indications for their use.
Accreditation
Accreditation Statement Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement Evolve Medical Education LLC designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
Paul G. Mathew, MD, DNBPAS, FAAN, FAHSProgram Moderator Assistant Professor of Neurology Harvard Medical School Headache/Sports Neurology/Concussion Specialist Brigham and Women’s Hospital/ Harvard Vanguard Medical Associates Boston, MA Meredith Barad, MD Clinical Associate Professor, Anesthesia (Pain Medicine), and Neurology & Neurological Sciences Program Director and Associate Division Chief, Pain Education Stanford Hospital and Clinics Redwood City, CA Wade Cooper, DO Clinical Associate Professor, Neurology and Anesthesiology Director, Headache & Neuropathic Pain University of Michigan Ann Arbor, MI Stephanie J. Nahas, MD, MSEd, FAHS, FAAN Director, Headache Medicine Fellowship Program Associate Professor, Department of Neurology Thomas Jefferson University Jefferson Headache Center Philadelphia, PA Umer Najib, MD, FAHS Associate Professor of Neurology Director, WVU Headache Center Program Director, Headache Medicine Fellowship Rockefeller Neuroscience Institute West Virginia University Morgantown, WV DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests:Paul G. Mathew, MD, DNBPAS, FAAN, FAHS, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Amgen, Biohaven Pharmaceuticals, Eli Lilly, Supernus, Theranica, and Teva. Meredith Barad, MD, and/or spouse/partner has no financial agreements or affiliation during the past year with commercial interests. Wade Cooper, DO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Amgen, Biohaven Pharmaceuticals, Dolor Technologies, Eli Lilly, Lundbeck, Teva, and Theranica. Stock/Shareholder: Dolor Technologies. Stephanie Nahas, MD, MSEd, FAHS, FAAN, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan/Abbvie, Amgen/Novartis, Biohaven Pharmaceuticals, Eli Lilly, Impel, Supernus, Teva, Theranica, Varsa, and Zosana. Speaker’s Bureau: Allergan/Abbvie, Amgen/Novartis, ElectroCare, Eli Lilly, Supernus, and Teva. Umer Najib, MD, FAHS, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speaker’s Bureau: Allergan. The Evolve staff, planners and peer reviewer have no financial relationships with commercial interests.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 08/25/2020

Overview

Learning Objectives

Accreditation

Faculty and Disclosures

System Requirements

Publication Dates

Title

Share on ReachMD